Magnetic Resonance Spectroscopy can aid in diagnosing and monitoring brain tumors by analyzing their chemical composition, distinguishing tumor types, tracking treatment progress, and detecting potential recurrence.
Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis
Traumatic Brain Injury
MRS offers insights into the evolving biochemical changes within the injured brain, such as reduced N-acetylaspartate (NAA) levels, which reflect neuronal damage, and the presence of lactate, which indicate ongoing metabolic stress. These metabolite alterations serve as critical markers, shedding light on the underlying mechanisms of TBI and guiding the development of tailored treatment strategies.
Magnetic Resonance Spectroscopy of Traumatic Brain Injury and Subconcussive Hits: A Systematic Review and Meta–Analysis
Magnetic Resonance Spectroscopy (MRS) aids tracking Parkinson’s Disease progression by quantifying metabolite changes in the substantia nigra and other relevant brain regions. It can measure alterations in metabolite concentrations, such as N-acetylaspartate (NAA) and myo-Inositol (mI), offering valuable markers for measuring disease progression.
Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis
MRS offers crucial insights into the underlying biochemical changes associated with Alzheimer’s Disease, such as reduced N-acetylaspartate (NAA) levels indicative of neuronal loss and increased myo-Inositol (mI) pointing to neuroinflammation. These specific metabolite markers enable healthcare professionals to monitor disease advancement and tailor interventions for Alzheimer’s patients as the condition evolves.
Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer’s Disease
MRS can play a crucial role in unraveling the intricate biochemical changes occurring in the epileptic brain. Elevated lactate levels point to heightened metabolic activity during seizures, while shifts in N-acetylaspartate (NAA) concentrations may indicate neuronal dysfunction. These unique metabolite profiles serve as invaluable indicators, enabling the tracking of epilepsy’s progression and the tailoring of personalized treatment approaches for individuals living with this neurological condition.
MRS offers key insights into the intricate biochemical changes associated with schizophrenia, such as alterations in glutamate and GABA levels, providing a window into the disorder’s neurochemical underpinnings. These specific metabolite profiles serve as valuable markers for tracking the evolution of schizophrenia and informing the development of tailored treatment approaches for affected individuals.
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data
Hypoxic Ischemic Encephalopathy
MRS provides critical insights into the dynamic biochemical changes within the injured brain, such as elevated lactate and decreased N-acetylaspartate (NAA), indicating oxygen deprivation and neuronal damage, respectively. These specific metabolite profiles offer valuable markers for monitoring the evolution of HIE and guiding the customization of treatment strategies for affected individuals.
COPYRIGHT © 2023 BRAINSPEC. ALL RIGHTS RESERVED.
RESEARCH USE ONLY. PENDING FDA CLEARANCE.